Nowadays, three FDA-approved predictive biomarkers are used for routine patient’s selection and those are (a) PD-L1 expression, (b) Microsatellite instability (MSI) and (c) tumor mutational burden (TMB) (172–174). This evidence concerns the gene CD274 and neoplasm.